Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Bioventix Plc LSE:BVXP London Ordinary Share GB00B4QVDF07 ORD 5P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -85.00 -2.12% 3,920.00 3,900.00 3,950.00 4,005.00 3,895.00 4,005.00 5,718 16:35:21
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 10.3 8.2 139.4 28.1 204

Bioventix Share Discussion Threads

Showing 1301 to 1322 of 1450 messages
Chat Pages: 58  57  56  55  54  53  52  51  50  49  48  47  Older
DateSubjectAuthorDiscuss
23/4/2021
17:49
Still nothing via my AJ Bell account.

The same thing happened with ABDP a few weeks ago when I got mine two working days after everyone with holdings elsewhere.

Not impressed.

jurgenklopp
23/4/2021
17:12
Yes - iWeb and ii
sharw
23/4/2021
12:44
Div received in HL a/c
alter ego
23/4/2021
11:36
YUP. Charles Stanley always on time.
igbertsponk
23/4/2021
11:05
Yes - through ii this am.
Suet

suetballs
23/4/2021
10:21
Anyone received their dividend yet ?
jurgenklopp
31/3/2021
16:35
I think Bioventix own 10%

Intuitive Investments Group plc

Investment in CardiNor AS

Intuitive Investments Group plc (AIM: IIG) ("IIG" or the "Company"), a closed-end investment company focussed on the life sciences sector, announces an investment of £125,000 to acquire ordinary shares in CardiNor AS ("CardiNor"), representing a 1.8 per cent. interest in CardiNor's enlarged share capital.

CardiNor is a Norwegian biotech company established in June 2015 to commercialise the development of secretoneurin ("SN"), an important new biomarker for cardiovascular disease ("CVD"). SN is the only biomarker shown to be associated with biological processes linked to cardiomyocyte handling. This unique biological function explains why SN presents as an independent and strong predictor of mortality in all major patient cohorts, including ventricular arrhythmia, acute heart failure, acute respiratory failure patients with CVD and severe sepsis. CardiNor has completed development of a research assay based on immunoassay technology to measure SN in blood and the assay is under further clinical development, including to obtain a CE mark. More information can be found at: hxxps://cardinor.com/ .

In the year ended 31 December 2020 , per CardiNor's unaudited management accounts, it achieved a loss after tax of approximately £141,000 and, as at 31 December 2020, had net assets of approximately £500,000, assuming an exchange rate of 11.87NOK/GBP.

valustar1
30/3/2021
08:35
Anything revealing at Mello on Biovenrix? Thanks N
nigeldoug1
29/3/2021
20:39
StrollingMolby,
Thank you for the explanation

piedro
29/3/2021
17:50
Piedro, yes I initially thought there must be a mistake or exceptional adjustments made, but then recalled the last half-year results to Dec'19 were restated due to a sales rebate not being entered into the accounting system, a pretty silly mistake really and not clear how that could have happened. This is from the correction note on 31 March 2020:

Correction - Unaudited Interim Results for the six months ended 31 December 2019

The Company has become aware that due to an administration error a sales rebate of $219k (£167k) was not entered into the accounting system. Consequently revenues for the six month period were £5.1m not the £5.3m as reported on 30 March 2020. Pre tax profits were £4.1m as opposed to £4.3m as previously stated. The cash figure and interim dividend remain unchanged.

HTTPS://www.investegate.co.uk/bioventix-plc--bvxp-/prn/correction---interim-results/20200331174737P8321/

strollingmolby
29/3/2021
16:14
Please can someone explain me the following ...

In these Interim Results
TURNOVER for the 6 months ended 31/12/2019 = £5,098,588
whereas from the previous Interim Results
TURNOVER for the 6 months ended 31/12/2019 = £5,265,270

.....

TIA.

piedro
29/3/2021
15:22
Wildshot - what is the point of incurring hedging cost and time on fx?

Why not just take the gains and losses as they arise instead of delaying them - which is all that hedging effectively does, at a cost.

trident5
29/3/2021
14:21
Hi Boros10, thanks for doing the session. If possible could you cover the forex management and whether they are likely to hedge in future to reduce the impact on margins by exchange gains/losses?
wildshot
29/3/2021
14:10
Leon - I second nigeldough1 - would like to understand more about the pollution project - sounds a bit different from the usual type of blood test.
sharw
29/3/2021
13:45
Investor's Champion comment:

As always, Bioventix swiftly converted profits into cash, with the operating cash inflow £3.3m and free cash inflow £3.2m, leaving period end cash of £5.8m well able to support a 20% increase in the first interim dividend to 43p per share.

energeticbacker
29/3/2021
08:58
Nice to see the word Cannabis in there!
igbertsponk
29/3/2021
08:33
LeonMany thanks for your post.What I would like to understand from Peter is how he plans to monetise the polution opportunity.ThanksNigel B
nigeldoug1
29/3/2021
07:26
"High-sensitivity troponin revenues from both Siemens Healthineers and licensees are estimated to have been c.£280k in the period, implying a more than doubling of revenues in H1 FY 2020, which implies sequential six-month growth of c.40%. Troponin now accounts for c.6% of revenues." From the finnCap research note which is available for free upon registration.
gsbmba99
29/3/2021
07:21
Topped up on open.
Suet

suetballs
29/3/2021
07:14
Boros10 - my question would be - is there a succession plan in place? Thanks.
trident5
29/3/2021
07:09
Good morning Boros10, I look forward to watching the interview this evening. As mentioned in my post earlier today, "Sales relating to troponin antibodies grew significantly once again during the period" - would be useful to get more detail on "grew significantly" in terms of numbers if possible.
spann_703
29/3/2021
07:01
With significant Covid 19 disruption from October through to the end of December and GBP advancing strongly against the USD and EUR I was braced for worse. Revenues for H1 21 were actually up 2% versus H2 2020 (sequential) which is encouraging. The business was hot badly following the initial global lockdowns in March 2020 with royalty revenues in H2 2020 dropping by as much as 26% over the previous six months. This dramatic decline was masked by a 48% sequential increase in purified SMA sales. It would have been helpful had management disclosed the royalty and purified SMA sale split for the period just ended but I imagine royalty revenues have partially recovered. I'll be quizzing Peter Harrison on this point and others on tonight's Mello Monday interview. If you have any questions you'd like me to ask Peter please let me know below.
boros10
Chat Pages: 58  57  56  55  54  53  52  51  50  49  48  47  Older
Your Recent History
LSE
BVXP
Bioventix
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

Log in to ADVFN
Register Now

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20230126 23:14:07